Medical reversal: why we must raise the bar before adopting new technologies.

作者: Adam Cifu , Vinay Prasad

DOI:

关键词:

摘要: Medical reversal occurs when a new clinical trial - superior to predecessors by virtue of better controls, design, size, or endpoints contradicts current practice. In recent years, we have witnessed several instances medical reversal. Famous examples include the class 1C anti-arrhythmics post-myocardial infarction (contradicted CAST trial) routine stenting for stable coronary disease COURAGE trial). this paper, explore phenomenon The causes and consequences are discussed. Conflicts interest among researchers an unyielding faith in basic science explored as root Reversal harms patients who undergo contradicted therapy during years it was favor those lag time before change Most importantly, creates loss system physicians patients. solution is upfront, randomized trials practices systematic method evaluate already existence.

参考文章(60)
G. VANHALEWEYK, K. BALAKUMARAN, J. LUBSEN, F. J. TEN CATE, A. JOVANOVIC, F. HAGEMEIJER, A. WlTHAGEN, B. C. P. POLAK, J. ROELANDT, P. G. HUGENHOLTZ, Flecainide: one-year efficacy in patients with chronic ventricular arrhythmias. European Heart Journal. ,vol. 5, pp. 814- 823 ,(1984) , 10.1093/OXFORDJOURNALS.EURHEARTJ.A061570
O.P. Heinonen, D. Albanes, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers The New England Journal of Medicine. ,vol. 330, pp. 1029- 1035 ,(1994)
Revascularization versus medical therapy for renal-artery stenosis. The New England Journal of Medicine. ,vol. 361, pp. 1953- 1962 ,(2009) , 10.1056/NEJMOA0905368
Writing Group for the Women's Health Initiative Investigators, Writing Group for the Women's Health Initiative Investigators, None, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA. ,vol. 288, pp. 321- 333 ,(2002) , 10.1001/JAMA.288.3.321
Holger Schünemann, Victor M. Montori, Emil H. Schemitsch, Dianne Jackowski, Jason W. Busse, Sheila Sprague, Mohit Bhandari, Derek Mears, Dianne Heels-Ansdell, P.J. Devereaux, Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials Canadian Medical Association Journal. ,vol. 170, pp. 477- 480 ,(2004)
Aaron S. Kesselheim, Jerry Avorn, The Role of Litigation in Defining Drug Risks JAMA. ,vol. 297, pp. 308- 311 ,(2007) , 10.1001/JAMA.297.3.308
Mark Friedberg, Bernard Saffran, Tammy J Stinson, Wendy Nelson, Charles L Bennett, Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology JAMA. ,vol. 282, pp. 1453- 1457 ,(1999) , 10.1001/JAMA.282.15.1453
A. F. Connors, The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators JAMA: The Journal of the American Medical Association. ,vol. 276, pp. 889- 897 ,(1996) , 10.1001/JAMA.276.11.889
Marcia L. Meldrum, A BRIEF HISTORY OF THE RANDOMIZED CONTROLLED TRIAL: From Oranges and Lemons to the Gold Standard Hematology-oncology Clinics of North America. ,vol. 14, pp. 745- 760 ,(2000) , 10.1016/S0889-8588(05)70309-9